Biocon enters commercialization agreement with Zentiva
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
The teams will assist the state health authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures
Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
The company will reduce wastage substantially, increase productivity, enhance environmental consciousness, save energy, optimally use natural resources, and expand its market penetration
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
The company sees the business reaching $100mn
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
Subscribe To Our Newsletter & Stay Updated